Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $748000.0.

  • Immunocore Holdings' Capital Expenditures fell 966.18% to $748000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 10964.26%. This contributed to the annual value of $5.2 million for FY2024, which is 464.52% down from last year.
  • As of Q3 2025, Immunocore Holdings' Capital Expenditures stood at $748000.0, which was down 966.18% from $414000.0 recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Capital Expenditures ranged from a high of $3.6 million in Q4 2024 and a low of $212000.0 during Q3 2023
  • For the 3-year period, Immunocore Holdings' Capital Expenditures averaged around $1.1 million, with its median value being $748000.0 (2025).
  • The largest annual percentage gain for Immunocore Holdings' Capital Expenditures in the last 5 years was 33867.81% (2024), contrasted with its biggest fall of 8567.14% (2024).
  • Over the past 3 years, Immunocore Holdings' Capital Expenditures (Quarter) stood at $817000.0 in 2023, then soared by 338.68% to $3.6 million in 2024, then plummeted by 79.13% to $748000.0 in 2025.
  • Its last three reported values are $748000.0 in Q3 2025, $414000.0 for Q2 2025, and $298000.0 during Q1 2025.